Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

This trial is testing asciminib — a newer type of drug that targets the BCR-ABL1 protein — as a first-line treatment for patients newly diagnosed with chronic myeloid leukemia (CML) in chronic phase (a blood cancer). **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with CML in chronic phase within the last 12 months - Your cancer is positive for the Philadelphia chromosome or BCR::ABL1 gene fusion - Your liver and kidneys are functioning adequately - You are willing to use contraception as required **You may NOT be eligible if...** - Your CML has progressed beyond the chronic phase to an accelerated or blast phase - You have received more than a few days of prior CML treatment (except hydroxyurea or brief courses of TKIs) - Your organ function falls below the required thresholds Talk to your doctor to see if this trial is right for you.